All News

In 58 patients undergoing excisional biopsy for discordant imaging and pathology, 16% had malignant pathology on excision; palpable lesions were the only factor independently associated with upstage to malignancy (adjusted OR 7.50).

Implementing in-office genetic testing at a diverse MedStar Georgetown breast oncology practice increased genetic counseling completion from 31.3% to 45.2% and lowered mean age at testing from 55.6 to 48.4 years, with gains across all racial groups.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed using IPSS-M criteria to detect hidden high-risk biology in lower-risk MDS.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss how sparing patients from IMiD-related GI toxicity and neutropenic infections with CELMoDs may extend treatment duration and progression-free survival.

In 167 patients with HR+/HER2− breast cancer after neoadjuvant chemotherapy, lymphovascular invasion, number of positive sentinel nodes, and >50% positive sentinel nodes were the strongest predictors of high axillary burden; a nomogram was developed to guide axillary management decisions.

This literature review of 10 studies found that anemia is common during NAC, with restrictive transfusion thresholds and intravenous iron supplementation showing favorable safety profiles, while ESA use and blood transfusions raised concerns about oncologic outcomes.

The RASolute 302 study of daraxonrasib was “the single biggest study presentation” at ASCO 2026, according to Sivraj Muralikrishnan, MD.

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, discuss the immunologic and mechanistic synergy between CELMoDs and standard myeloma backbone therapies.

A decision tree cost-utility analysis found ICG more cost-effective than methylene blue for SLNB in breast cancer (ICER $4,044/QALY), with Monte Carlo simulation showing an 80% probability of ICG superiority.

Compared with wire-guided needle localization, MOLLI localization was associated with shorter median OR delays, fewer overall delays, and an estimated combined annual opportunity cost benefit of nearly $673,000.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discuss how long-term COMMANDS data support the use of luspatercept.

Experts focused on lymphoma cellular therapy convened to discuss CAR T-cell candidacy and practical barriers to access for patients with DLBCL.

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, explain how mezigdomide’s complete cereblon E3 ligase engagement overcomes IMiD resistance in heavily pretreated multiple myeloma.

Early adoption of the MOLLI wireless localization system demonstrated a rapid learning curve, fewer missed biopsy clips, and a significant reduction in operating room delays compared with traditional needle localization.

In 161 biopsied breast masses, malignant lesions showed significantly higher E-strain ratios than benign lesions (3.51 vs 1.93), with progressive increases across BI-RADS categories, supporting elastography as an adjunct to biopsy decision-making.

Amer Zeidan, MBBS, MD, discussed when to start luspatercept at the full 1.75 mg/kg dose in lower-risk MDS based on the MAXILUS trial.

Patients with clinically higher-risk disease but favorable GPS results had higher 6-year EFS rates across treatment arms vs those at a lower clinical risk.

Nicholas Hornstein, MD, PhD, ranks RASolute 302, BREAKWATER, MATTERHORN, and more in a real-time discussion on Double Blind.

Experts discuss how to navigate coding, reimbursement, and other potential financial strains when treating patients via radiotherapy.

This literature review and institutional case report describes primary NECB with synchronous pancreatic and liver metastases as an extraordinarily rare, aggressive phenotype requiring multidisciplinary management driven by tumor biology rather than surgery.

Post-surgical pyoderma gangrenosum was successfully managed following bilateral mastectomy after clinical recognition prompted a shift to immunosuppressive therapy, avoiding further surgical debridement and achieving eventual wound healing.

At EHA, Benoit Tessoulin, MD, PhD, shared data showing the epcoritamab/R² combination benefitted all relapsed/refractory follicular lymphoma subgroups.

FDA breakthrough designation and NCCN inclusion elevate Merlin CP-GEP as a tool to refine SLNB decisions in T1b/T2a melanoma, per MERLIN_001 trial data.

Updated phase 2a data showed durable survival in a small subset of heavily pretreated patients with advanced pancreatic cancer treated with namodenoson.

Full phase 3 MANGROVE trial data will be presented at an upcoming medical meeting, with global regulatory submissions planned for the second half of 2026.

“[Epcoritamab/R2] is a good option for [patients] at first relapse or even further, even if they are very high risk,” said Benoit Tessoulin, MD, PhD.

In this retrospective cohort study, it was shown that acute pancreatitis hospitalizations occurred more frequently in patients with multiple myeloma who were older and more medically complex.

Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission.

The MagUS magnetically-guided ultrasound biopsy technique enabled successful sentinel lymph node biopsy de-escalation in 7 patients who preferred axillary evaluation to surgical staging, with all pathology returning negative.

Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell–based immunotherapy.